Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2025Drug Design Development and TherapyOpen Access

Population Pharmacokinetic/Pharmacodynamic Modeling of Tacrolimus in Renal Transplant Recipients: Impact of CYP3A5 Genotype and Wuzhi Capsule Co-Medication

View Full Paper
Ask AI
Bookmark
Share

Authors

QXQinfang XiangYYYi YangGLGuoxing Li

Discussion

Loading...

Member takes

Overview

Population pharmacokinetic/pharmacodynamic modeling reveals tacrolimus interactions in renal transplant patients, indicating genotype and co-medication effects.

Key Points

  • The study quantified relationships between tacrolimus dose, exposure, and adverse effects in renal transplant patients.
  • Patients with CYP3A5*3/*3 genotype who received Wuzhi capsules faced increased risks of kidney damage even with lower tacrolimus doses.
  • Age and hemoglobin levels significantly influenced baseline fasting plasma glucose and estimated glomerular filtration rate in patients.
  • The developed models support tailored tacrolimus dosing, potentially improving outcomes for renal transplant recipients.

Cite This Study

Xiang et al. (2025) studied this question.

synapsesocial.com/papers/68d46ccf31b076d99fa69161https://doi.org/10.2147/dddt.s542786
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Population pharmacokinetics of tacrolimus and CYP3A5-driven variability: implications for model-informed dose individualization in pediatric renal transplant recipients2026
  2. 2Population Pharmacokinetic/Pharmacodynamic Model of the Impact of Cumulative Tacrolimus Exposure on Kidney Function After Liver Transplant2025 · 1 citations
  3. 3Guiding the starting dose of the once-daily formulation of tacrolimus in “de novo” adult renal transplant patients: a population approach2024 · 3 citations
  4. 4Population pharmacokinetic characteristics of tacrolimus in Chinese lung transplant recipients and optimisation of dosing regimen during the early post-transplantation phase2025 · 1 citations
  5. 5Refining tacrolimus dosing through CYP3A5 pharmacogenetics in Taiwanese renal transplant recipients2025 · 3 citations